Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells

Genetically engineered oncolytic herpes simplex virus-1 (HSV-1) vectors selectively replicate in tumor cells causing direct killing whereas sparing normal cells. One clinical limitation of using oncolytic HSV vectors is their attenuated growth. We hypothesized that the appropriately chosen chemother...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer gene therapy 2009-07, Vol.16 (7), p.551-560
Hauptverfasser:	Passer, B J, Castelo-Branco, P, Buhrman, J S, Varghese, S, Rabkin, S D, Martuza, R L
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Antitumor activity Apoptosis Biomedical and Life Sciences Biomedicine Care and treatment Cell death Cell Line, Tumor Enzyme-Linked Immunosorbent Assay Flow Cytometry Gene Expression Gene Therapy Genetic aspects Genetic engineering Genetic Vectors - genetics Genetic Vectors - physiology Health aspects Herpes simplex Herpes simplex virus Herpes simplex virus 1 Herpes viruses Herpesvirus 1, Human - genetics Herpesvirus 1, Human - physiology Histones Humans Male Mitosis Oncolysis Oncolytic Virotherapy - methods original-article Paclitaxel Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - therapy Simplexvirus - genetics Simplexvirus - physiology Stathmin Synergism Taxanes Taxoids - therapeutic use Tumor cells Virus Replication
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!